Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Authors:

Abstract
As patents on originator biological disease-modifying anti-rheumatic drugs (bDMARDs) expire, biosimilar drugs are marketed. As a result of the complex manufacturing processes, a biosimilar is not c...
Funding Information
  • AbbVie (Unrestricted grant)